Thus, noninvasive in vivo monitoring of CD4+ cells with CD4-specific immunotracers holds the promise of providing valuable insights into the efficacy of cancer immunotherapy and will facilitate a better understanding of T-cell-based immunotherapies and CD4+ T-cell-mediated immune responses in immune-mediated inflammatory diseases. This evidence concerns the gene CD4 and cancer.